TRANSITION (NASDAQ:TTHI)
7.55
+0.05 (0.67%)
| TRANSITION (NASDAQ:TTHI) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $7.50 | 52 Week High | $9.00 | ||
| Open | $7.60 | 52 Week Low | $2.00 | ||
| Day High | $7.60 | P/E | N/A | ||
| Day Low | $7.45 | EPS | $0.00 | ||
| Volume | 12,850 | ||||
| More TTHI Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| TTH | 3 | ELN | 3 |
| CIT | 2 | LCC | 1 |
| CSE | 1 | AAPL | 1 |
| QDEL | 1 | OSIP | 1 |
| DAVE | 1 | WGOV | 1 |
| LNET | 1 | CSE | 1 |
Entities who have mentioned TTHI
- StreetInsider.com Morning Movers | View Related Stories »
- EIM Group | View Related Stories »
- Piper Jaffray | View Related Stories »
- JPMorgan | View Related Stories »
- Citi | View Related Stories »
- Credit Suisse | View Related Stories »
- Jefferies & Co | View Related Stories »
- Collins Stewart | View Related Stories »
- Canaccord Adams | View Related Stories »
- JANA Partners LLC | View Related Stories »
- Barry Rosenstein | View Related Stories »
- Roth Capital | View Related Stories »
View All ReportsStreetInsider.com Reports on TTHI
- Transition Therapeutics (TTHI) $75 Million Mixed Securities Shelf
- Morning Movers 7/13: IBAS, CYTR, IRE, TTHI, OSIP Higher; BEAT, ADY, CIT, CSE, CEDC Lower
- Elan (ELN) and Transition Therapeutics Announce Phase 1 Data Showing ELND005 Achieves Desired Concentrations in Brain Tissue and Cerebrospinal Fluid
- Morning Movers 4/23: LNET, TAST, WGOV, ACOR, TTHI, RSH Higher; CNMD, VMW, SANM, NCR, JAKK Lower
View All Press ReleasesCompany Press Releases on TTHI
- Transition Therapeutics Announces First Quarter Fiscal 2010 Financial Results
- Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2010 Financial Results on Tuesday, November 10th, at 4:30 P.M. EST
- Transition Therapeutics Files Shelf Registration Statement
StreetInsider Reports on TTHI by Category
View All BlogsBlogs on TTHI
- Six Canadian Life Sciences Stocks
- Transition Therapeutics Boost From Eli Lilly Deal Short-Lived
- Transition Therapeutics Up on News of Eli Lilly Colaboration
Comments on TTHI
No comments are currently available.
